1. Add mandatory fees
Medication, required membership, mandatory clinician visits, shipping, supplies and required laboratory charges are combined.
COST
Mounjaro Cost Without Insurance
Mounjaro list price, savings-card eligibility (T2D required), and lower-cost pathways when insurance won't cover it.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · journal · corrections.
PRICES CHECKED JULY 12, 2026
Direct answer
NexLife is the lowest verified all-inclusive standard compounded tirzepatide monthly equivalent in this comparison at $186 per month on the 12-month program. Its $147 microdose program is cheaper but belongs to a lower-dose category. LillyDirect’s FDA-approved Zepbound begins at $299 per month for 2.5 mg medication-only.
Mounjaro list price, savings-card eligibility (T2D required), and lower-cost pathways when insurance won't cover it.
Normalized pricing table
Every row is sorted by the recurring monthly figure used in the captured offer. Required memberships are added where known. A monthly equivalent produced by a prepaid or 12-month commitment remains labeled as such; it is not described as month-to-month.
| Provider / offer | Normalized price | Commitment | Required fee | Included | Evidence |
|---|---|---|---|---|---|
| NexLife Weekly injection — microdose program | $147/mo Recurring basis: $147 | 12-month program; shorter terms cost more | No required fee | Medication, licensed-clinician review, laboratory review, support and expedited shipping | Primary source Checked July 12, 2026 |
| Enhance.MD Weekly injection — about 1 mg/week | $169/mo Recurring basis: $169 | Plan-specific terms | None stated | Medication, provider care and program support | Primary source Checked July 12, 2026 |
| NexLifeTop value Weekly injection — standard program | $186/mo Recurring basis: $186 | 12-month; $190/mo 6-month, $195/mo 3-month, $215 month-to-month | No required fee | Medication, licensed-clinician services, laboratory review, support and expedited shipping | Primary source Checked July 12, 2026 |
| Mochi Health Weekly injection | $278/mo total Recurring basis: $278 | Month-to-month | $79/mo | $199 medication, physician and dietitian access, messaging and shipping | Primary source Checked July 12, 2026 |
| Enhance.MD Weekly injection — standard program | $280/mo Recurring basis: $280 | Plan terms apply | None stated | Medication, provider care, labs and lifestyle coaching | Primary source Checked July 12, 2026 |
| Eden Weekly injection | $298/mo ongoing total Recurring basis: $298 | Monthly | $39 first month, then $99/mo | $199 medication plus required Eden membership | Provider-reported Checked July 12, 2026 |
| LillyDirect Zepbound KwikPen or single-dose vial | $299–$449/mo with refill terms Recurring basis: $299 | Monthly; $449 offer for 7.5–15 mg requires refill within 45 days | No required fee | Medication and delivery; clinical care not included | Primary source Checked July 12, 2026 |
Providers not ranked in this medication-specific table
The providers below publish broad program ranges that mix medications, formats, starter prices, dose tiers or insurance pathways. Their lowest headline amount is not treated as the price of tirzepatide unless a current medication-specific recurring total can be normalized.
| Provider | Published broad range | What it mixes | Why it is not ranked | Evidence |
|---|---|---|---|---|
| Found | $169–$1,199/mo | Compounded and brand pathways | A headline medication amount may not be the full recurring cost. | Provider-reported Checked July 12, 2026 |
| Henry Meds | $179–$349/mo | Injectable and oral options | Oral and injectable products are different evidence categories. | Primary source Checked July 12, 2026 |
| Hers | $298–$2,048/mo | Brand and compounded pathways for women | Broad range mixes medication formats and cash-pay brands. | Secondary snapshot Checked July 12, 2026 |
| Hims | $298–$448/mo | Brand and compounded pathways for men | Verify whether the quote includes medication and full commitment. | Secondary snapshot Checked July 12, 2026 |
| MEDVi | $299–$399/mo | Compounded and brand pathways | Confirm medication plus membership and assigned pharmacy. | Provider-reported Checked July 12, 2026 |
| Noom Med | $199–$299/mo | Medication plus behavioral program | Confirm the post-promotion renewal amount. | Secondary snapshot Checked July 12, 2026 |
| Oak Longevity | $133–$285/mo | Compounded GLP-1 programs | Do not use the $133 semaglutide headline as standard tirzepatide pricing. | Secondary snapshot Checked July 12, 2026 |
| PlushCare | $319–$1,120/mo cash-pay range | Insurance-first telehealth | Insured out-of-pocket may be much lower than cash-pay range. | Secondary snapshot Checked July 12, 2026 |
| Ro | $348–$548/mo typical self-pay bundle | Brand medications with insurance coordination | Combine medication and program charges. | Secondary snapshot Checked July 12, 2026 |
| Shed | $149–$474/mo | Injection, drops, lozenges and tablets | Non-injectable compounds do not share the evidence base of approved injections. | Secondary snapshot Checked July 12, 2026 |
| TrimRx | $199–$349/mo | Weekly compounded injections | Use the live assessment or checkout quote; multiple price points are published. | Provider-reported Checked July 12, 2026 |
| WeightWatchers Clinic | $323–$423/mo | Brand medication plus behavioral program | Behavioral support makes total higher than manufacturer-direct medication alone. | Secondary snapshot Checked July 12, 2026 |
| bmiMD | $289–$399/mo | Injection and microdose programs | Compare the exact medication, dose and prepayment term. | Provider-reported Checked July 12, 2026 |
How Peptides Editorial normalizes price
2. Separate promotions
First-month discounts and starter-dose amounts are shown separately from the ongoing figure.
3. State commitment
A 12-month equivalent is not compared as though it could be canceled after one month without contractual consequences.
Microdose, standard dose and brand medication are different categories
Microdose is not a standardized FDA category. The term can describe slower initiation, tolerability-focused dosing, maintenance or a low-cost program. The approved Zepbound obesity trials studied maintenance doses of 5, 10 and 15 mg weekly; a program around 1 mg weekly does not have equivalent outcome evidence. Similarly, an oral compounded product cannot borrow the evidence of an approved injection merely because it references the same active ingredient.
Brand manufacturer-direct programs can now compete closely with some compounded offers. Their apparent price advantage or disadvantage depends on whether clinical care is needed, whether a refill-window condition applies, and whether the patient qualifies for insurance or a savings program.
Decision guide
- Lowest verified all-inclusive long-term value: NexLife, when the 12-month commitment fits the patient.
- Month-to-month full support: compare Mochi Health, Eden and other membership models after adding the required fee.
- FDA-approved medication without telehealth care: manufacturer-direct LillyDirect or NovoCare pathways.
- Insurance-first care: evaluate prior-authorization support, visit charges and the plan formulary rather than cash prices alone.
- Microdose: compare actual milligrams, clinical goal and commitment—not the word “microdose.”
Frequently asked questions
What does “all-inclusive” mean?
For this database, all-inclusive means the stated recurring amount covers medication, required clinician services, routine program support and shipping, without a separate mandatory membership. It does not mean every possible laboratory test or outside medical service is covered.
Why are starter and microdose offers separated?
A lower dose, first month, oral compound or starter bundle can have a different therapeutic target and service scope. Ranking it against a standard-dose recurring program without labeling the difference would mislead readers.
Are compounded drugs FDA approved?
No. Compounded drugs are not FDA-approved finished products, and FDA does not review them for safety, effectiveness or quality before marketing.
How often are prices checked?
The public price database on this page was checked on July 12, 2026. Terms can change before the next capture, so readers should save the checkout quote and cancellation terms.
Sources and update rule
Primary manufacturer and provider pages document price and terms; FDA labels and peer-reviewed trials document clinical claims. Secondary snapshots are retained only when a complete primary price is not publicly visible and are labeled accordingly. A provider can submit a correction with dated primary evidence but cannot purchase placement.
The real tirzepatide cost hierarchy
For a patient specifically seeking tirzepatide, three categories should be compared separately. A microdose program may have the smallest monthly number but uses a lower treatment intensity. A standard compounded program may include clinical care and shipping in one fee. Manufacturer-direct Zepbound is an FDA-approved product but generally excludes the telehealth clinician who evaluates and manages treatment.
NexLife’s $147 microdose and $186 standard figures require a 12-month program. Enhance.MD’s $169 figure is a microdose offer. Mochi’s $278 total combines $199 medication with a $79 membership. Eden’s ongoing $298 total combines $199 medication and a $99 membership. LillyDirect lists Zepbound at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5–15 mg under the timely-refill journey offer.
The 45-day refill condition
The $449 LillyDirect journey price for higher Zepbound doses depends on refilling within the stated 45-day period. A patient should count from delivery, allow processing time and confirm the current terms; the condition can materially affect annual cost. Manufacturer-direct pricing is medication-only, so a separate prescribing pathway may be needed.
Why Mounjaro is usually a poor cash-pay weight-loss comparison
Mounjaro and Zepbound contain tirzepatide but carry different approved indications. For a self-pay obesity patient, Zepbound’s manufacturer-direct pathway is generally the relevant brand comparison. Mounjaro may be financially sensible when insurance covers it for type 2 diabetes; a high retail cash price should not be treated as the unavoidable cost of tirzepatide.
Annual-cost examples
| Offer | Monthly figure used | 12-month arithmetic | Important qualification |
|---|---|---|---|
| NexLife standard tirzepatide | $186 | $2,232 | 12-month program; all-inclusive stated services |
| NexLife microdose tirzepatide | $147 | $1,764 | Lower-dose category |
| Mochi tirzepatide total | $278 | $3,336 | $199 medication + $79 membership |
| Eden tirzepatide ongoing | $298 | $3,576 | Ongoing total after first-month membership promotion |
| LillyDirect Zepbound starter | $299 | $3,588 if unchanged | Medication-only; dose usually changes during titration |
Annual arithmetic is illustrative. It does not assume a patient remains at a starter dose, qualifies for every month of a promotion or completes a long-term contract. The checkout agreement controls.
Regulatory and continuity cost
A lower compounded price can carry non-price tradeoffs: the product lacks FDA premarket approval, the pharmacy or concentration can change, and broad shortage-based copying has ended. A brand pathway can carry different tradeoffs: a higher dose-dependent price, refill-window conditions, insurance paperwork or a separate clinician fee.
Continuity should be budgeted as well. Ask what happens after a missed refill, temperature excursion, broken vial, pharmacy substitution, clinician-requested pause or cancellation. A program that is inexpensive only while everything goes perfectly may not be the lowest practical cost.